Zomedica Launches the PulseVet Acoustic Muffler(TM) Accessory for PulseVet(R) Shock Wave System
Rhea-AI Summary
Zomedica (OTCQB: ZOMDF) announced the launch of the PulseVet Acoustic Muffler(TM), an accessory for PulseVet(R) shock wave therapy systems designed to significantly reduce treatment noise while maintaining energy delivery and clinical efficacy. The muffler redirects and dampens unnecessary noise without altering the therapeutic beam, aiming to create a quieter environment for veterinarians, patients, and caregivers.
The accessory integrates simply with existing PulseVet systems and is intended for musculoskeletal and orthopedic applications. According to Zomedica, the U.S. total addressable market for its product suite exceeds $2 billion, 2025 revenue grew 17% to $32 million, and liquidity was about $48 million as of March 31, 2026.
Positive
- Launch of PulseVet Acoustic Muffler expands PulseVet shock wave system accessory offering
- 2025 revenue grew 17% to $32 million
- Liquidity of approximately $48 million as of March 31, 2026
- Total addressable U.S. market for product suite exceeds $2 billion
Negative
- None.
News Market Reaction – ZOMDF
In the Aug 4 session, ZOMDF declined 3.37%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The accessory reduces sound in the treatment environment while maintaining the trusted efficacy of PulseVet® shock wave therapy
ANN ARBOR, MI / ACCESS Newswire / August 4, 2026 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), an animal health company offering innovative point-of-care diagnostic and therapeutic products for equine and companion animals, today announced the launch of the PulseVet Acoustic Muffler, an innovative accessory designed to significantly reduce the acoustic noise associated with shock wave therapy treatments while preserving the clinical performance practitioners rely on.
Developed for use with PulseVet shock wave therapy systems, the PulseVet Muffler™ accessory addresses the treatment noise associated with the sound waves produced by the PulseVet system. By reducing sound levels during therapy sessions, the muffler helps create a more comfortable experience for patients, clinicians, and caregivers - without affecting energy delivery and therefore maintaining clinical efficacy.
"At Zomedica, innovation begins with listening to our customers," said Larry Heaton, CEO. "Veterinarians have consistently told us they value the proven clinical outcomes delivered by PulseVet shock wave therapy but would welcome a quieter treatment experience. The new muffler delivers exactly that - meaningful noise reduction while preserving the shock waves producing the therapeutic efficacy that has made the PulseVet shock wave system the trusted choice in veterinary medicine."
The PulseVet Acoustic Muffler accessory was engineered to integrate seamlessly with existing PulseVet systems, allowing clinics to enhance the treatment environment without altering established protocols. The accessory preserves the performance characteristics necessary to deliver effective shock wave therapy for a variety of musculoskeletal and orthopedic conditions.
"Sometimes the biggest innovations aren't about changing how a treatment works - they're about improving the experience," said Bill Campbell, VP of Imaging, and inventor of the muffler. "Our design redirects and dampens the unnecessary noise produced by the shockwave device without affecting the therapeutic beam, creating a quieter treatment environment without compromising performance."
Key Benefits of the PulseVet Acoustic Muffler accessory:
Reduced treatment noise to improve the clinical environment
No change to the shock waves producing clinical efficacy and therapeutic performance
Maintains energy delivery characteristics required for effective treatment
Simple integration with PulseVet® shock wave therapy systems
Veterinary practices can benefit from a quieter treatment setting that may help reduce anxiety associated with loud procedural sounds, while continuing to leverage the proven shock wave technology to support healing, pain management, and improved mobility in animal patients.
The PulseVet Muffler™ accessory is available directly through Zomedica.
About Zomedica
Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians with innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi Loop® line of therapeutic devices and the TRUFORMA® diagnostic platform, the TRUVIEW® digital cytology system, the VetGuardian PLUS™ Zero Touch® monitoring system and VETIGEL® hemostatic gel, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds
Follow Zomedica
Email Alerts: http://investors.zomedica.com
Facebook: https://m.facebook.com/zomedica
X (formerly Twitter): https://twitter.com/zomedica
Instagram: https://www.instagram.com/zomedica_inc
Cautionary Note Regarding Forward-Looking Statements
Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements and our ability to realize upon our business plans and cost control efforts.
Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether the new development services will continue; the outcome of clinical studies; the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments; uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, including international efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to realize the anticipated growth opportunities from our acquisitions; uncertainty as to our ability to supply products in response to customer demand; supply chain risks associated with tariff changes; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products and purchase of consumables following adoption of our capital equipment; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at www.sedarplus.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.
The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.
Investor Relations Contact:
Zomedica Investor Relations
investors@zomedica.com
1-734-369-25
SOURCE: Zomedica Corp.
View the original press release on ACCESS Newswire